ono-1301 and Hypertension--Pulmonary

ono-1301 has been researched along with Hypertension--Pulmonary* in 7 studies

Reviews

2 review(s) available for ono-1301 and Hypertension--Pulmonary

ArticleYear
[Prostacyclin derivatives].
    Nihon rinsho. Japanese journal of clinical medicine, 2008, Volume: 66, Issue:11

    Epoprostenol (prostacyclin) has been shown to improve survival in pulmonary arterial hypertension. However, this therapy needs continuous intravenous administration devises because of its short half-life. Recently, an orally active prostacyclin analogue, beraprost sodium, and its drug delivery system have been developed in Japan. Beraprost sodium improves pulmonary hemodynamics in patients with pulmonary arterial hypertension. In addition, we have developed ONO-1301, a novel long-acting prostacyclin agonist with thromboxane synthase inhibitory activity. Subcutaneous administration of ONO-1301 markedly attenuated monocrotaline-induced pulmonary hypertension and improved survival in rats. These prostacycline derivates may be promising for the treatment of pulmonary arterial hypertension.

    Topics: Epoprostenol; Humans; Hypertension, Pulmonary; Pyridines

2008
Non-prostanoid prostacyclin agonists for the treatment of pulmonary arterial hypertension.
    Expert opinion on investigational drugs, 2006, Volume: 15, Issue:3

    Topics: Animals; Drug Evaluation, Preclinical; Drugs, Investigational; Epoprostenol; Humans; Hypertension, Pulmonary; Pyridines

2006

Other Studies

5 other study(ies) available for ono-1301 and Hypertension--Pulmonary

ArticleYear
Innovative therapeutic strategy using prostaglandin I
    Scientific reports, 2021, 03-31, Volume: 11, Issue:1

    Clinical outcomes of pulmonary arterial hypertension (PAH) may be improved using targeted delivery system. We investigated the efficacy of ONO1301 (prostacyclin agonist) nanospheres (ONONS) in Sugen5416/hypoxia rat models of PAH. The rats were injected with saline (control) or ONONS (n = 10, each) on days 21 and 28, respectively. Hepatocyte growth factor (HGF)-expressing fibroblasts and inflammatory cytokines were measured. Cardiac performance was assessed and targeted delivery was monitored in vivo, using Texas red-labeled nanoparticles. Compared with control, HGF-expressing fibroblasts and HGF expression levels were significantly higher in the ONONS group, while the levels of interleukin-6, interleukin-1β, transforming growth factor-β, and platelet-derived growth factor were lower. Histological assessment revealed significant amelioration of the percent medial wall thickness in pulmonary vasculature of rats in the ONONS group. Rats in the ONONS group showed decreased proliferating cell nuclear antigen-positive smooth muscle cells and improved right ventricle pressure/left ventricle pressure. No difference was seen in the accumulation of Texas red-labeled nanoparticles in the brain, heart, liver, and spleen between PAH and normal rats. However, a significant area of nanoparticles was detected in the lungs of PAH rats. ONONS effectively ameliorated PAH, with selective delivery to the damaged lung.

    Topics: Animals; Antihypertensive Agents; Cells, Cultured; Epoprostenol; Fibroblasts; Hepatocyte Growth Factor; Hypertension, Pulmonary; Interleukins; Male; Myocytes, Smooth Muscle; Nanocapsules; Platelet-Derived Growth Factor; Pulmonary Artery; Pyridines; Rats; Rats, Sprague-Dawley; Transforming Growth Factor beta

2021
Oral administration of a novel long-acting prostacyclin agonist with thromboxane synthase inhibitory activity for pulmonary arterial hypertension.
    Circulation journal : official journal of the Japanese Circulation Society, 2013, Volume: 77, Issue:8

    Continuous administration of prostacyclin has improved the survival of patients with pulmonary arterial hypertension (PAH). However, this treatment has some problems, including its short duration of activity and difficult delivery. Therefore, we developed ONO-1301, an orally active, long-acting prostacyclin agonist with thromboxane synthase inhibitory activity.. We investigated whether oral administration of ONO-1301 can both prevent and reverse monocrotaline (MCT)-induced PAH in rats. Rats were randomly assigned to receive repeated oral administration of ONO-1301 twice daily beginning either 1 or 8 days after subcutaneous injection of MCT. A control group received oral saline, and a sham group received a subcutaneous injection of saline instead of MCT. MCT-treated controls developed significant pulmonary hypertension. Treatment with ONO-1301 from day 1 or 8 significantly attenuated the increases in right ventricular systolic pressure and the increase in medial wall thickness of pulmonary arterioles. Kaplan-Meier survival curves demonstrated that the effect of ONO-1301 was equivalent to that of an endothelin receptor antagonist and a phosphodiesterase-5 inhibitor. A single oral dose of ONO-1301 increased plasma cAMP levels for up to 6h. Treatment with ONO-1301 significantly decreased urinary 11-dehydro-thromboxane B2 and increased the plasma hepatocyte growth factor concentration.. Oral administration of ONO-1301 ameliorated PAH in rats, an effect that may occur through cAMP and hepatocyte growth factor.

    Topics: Animals; Blood Pressure; Epoprostenol; Hepatocyte Growth Factor; Humans; Hypertension, Pulmonary; Male; Monocrotaline; Pyridines; Rats; Rats, Wistar; Thromboxane B2; Thromboxane-A Synthase

2013
Novel oral prostacyclin analog with thromboxane synthase inhibitory activity for management of pulmonary arterial hypertension.
    Circulation journal : official journal of the Japanese Circulation Society, 2013, Volume: 77, Issue:8

    Topics: Animals; Epoprostenol; Humans; Hypertension, Pulmonary; Male; Monocrotaline; Pyridines; Thromboxane-A Synthase

2013
Single injection of a sustained-release prostacyclin analog improves pulmonary hypertension in rats.
    American journal of respiratory and critical care medicine, 2008, Jan-15, Volume: 177, Issue:2

    Although prostacyclin is recognized as a therapeutic breakthrough for pulmonary hypertension, it needs continuous infusion because of its short action. Therefore, we developed a new drug delivery system for prostacyclin. We prepared ONO-1301MS, a novel sustained-release prostacyclin analog polymerized with poly(d,l-lactic-co-glycolic acid) (PLGA) microspheres.. We examined whether ONO-1301MS attenuates monocrotaline (MCT)-induced pulmonary hypertension in rats, and attempted to elucidate the underlying mechanisms responsible for the beneficial effects of ONO-1301MS.. After MCT injection, rats were randomized to receive a single subcutaneous injection of 100 mg/kg ONO-1301MS or vehicle.. We prepared ONO-1301MS, which was polymerized with PLGA to release ONO-1301 for 3 weeks. A single administration of ONO-1301MS achieved sustained elevation of its circulating level and plasma cyclic adenosine 3',5'-monophosphate level for 3 weeks, and attenuated an increase in a metabolite of thromboxane A(2) level. Rats had developed pulmonary hypertension 3 weeks after MCT injection; however, treatment with ONO-1301MS significantly attenuated the increases in right ventricular systolic pressure and right ventricular weight to body weight ratio. ONO-1301MS significantly inhibited hypertrophy of pulmonary arteries. Phosphorylation of extracellular signal-regulated protein kinase (ERK) in the lung was significantly increased in the control group, whereas this increase was markedly attenuated by treatment.. We developed a new drug delivery system for prostacyclin using PLGA and ONO-1301. A single injection of ONO-1301MS resulted in sustained activity for 3 weeks, and attenuated pulmonary hypertension, partly through its antiproliferative effect on vascular smooth muscle cells via inhibition of ERK phosphorylation.

    Topics: Animals; Antihypertensive Agents; Delayed-Action Preparations; Disease Models, Animal; Drug Compounding; Epoprostenol; Extracellular Signal-Regulated MAP Kinases; Hemodynamics; Hypertension, Pulmonary; Injections, Subcutaneous; Male; Microspheres; Monocrotaline; Pyridines; Rats; Rats, Wistar; Thromboxane-A Synthase

2008
A long-acting prostacyclin agonist with thromboxane inhibitory activity for pulmonary hypertension.
    American journal of respiratory and critical care medicine, 2005, Dec-15, Volume: 172, Issue:12

    The balance between prostacyclin and thromboxane plays an important role in the regulation of pulmonary vascular tone. Recently, we developed ONO-1301, a novel, long-acting prostacyclin agonist with thromboxane synthase inhibitory activity.. We investigated whether modulation of prostacyclin/thromboxane balance by ONO-1301 ameliorates monocrotaline-induced pulmonary hypertension in rats.. After subcutaneous injection of monocrotaline or vehicle, rats were randomized to receive repeated subcutaneous administration of ONO-1301 or vehicle twice per day for 3 wk.. There was significant development of pulmonary hypertension 3 wk after monocrotaline injection. Treatment with ONO-1301 significantly attenuated the increases in right ventricular systolic pressure and ratio of right ventricular weight to body weight in monocrotaline rats. Furthermore, ONO-1301 significantly attenuated the increase in medial wall thickness of peripheral pulmonary arteries in monocrotaline rats. The half-life of plasma ONO-1301 concentration after a single subcutaneous administration was approximately 5.6 h. A single administration of ONO-1301 increased plasma cyclic adenosine 3', 5'-monophosphate level, which lasted at least up to 8 h. Treatment with ONO-1301 significantly decreased plasma 11-dehydro-thromboxane B2, a metabolite of thromboxane, in monocrotaline rats. Finally, Kaplan-Meier survival curves demonstrated that repeated administration of ONO-1301 improved survival rate in monocrotaline rats compared with vehicle administration (80 vs. 30% in 6-wk survival).. Subcutaneous administration of a novel prostacyclin agonist (ONO-1301) markedly attenuated monocrotaline-induced pulmonary hypertension and improved survival in rats. The beneficial effects of ONO-1301 may occur through its long-lasting stimulation of cyclic adenosine 3', 5'-monophosphate and inhibition of thromboxane synthase.

    Topics: Animals; Blood Pressure; Epoprostenol; Heart Rate; Hypertension, Pulmonary; Injections, Subcutaneous; Male; Monocrotaline; Pyridines; Rats; Rats, Wistar; Thromboxane B2; Thromboxane-A Synthase

2005